Michael Kavanaugh - CytomX Therapeutics Executive
CTMX Stock | USD 2.19 0.08 3.79% |
Executive
Mr. W. Michael Kavanaugh, M.D. serves as a Chief Scientific Officer and Head Research and NonClinical Development of the company. Dr. Kavanaugh joined us as chief scientific officer and head of research and nonclinical development in January 2015. Prior to joining us, Dr. Kavanaugh was senior vice president and chief scientific officer of Five Prime Therapeutics, Inc. From February 2009 to December 2014, Dr. Kavanaugh held multiple positions in research and development at Five Prime Therapeutics, Inc. and led the growth of its therapeutic pipeline. Prior to that, Dr. Kavanaugh served as vice president of Novartis Vaccines Diagnostics, Inc. and executive director of Oncology Biologics in the Novartis Institutes of Biomedical Research. He joined Novartis as part of its acquisition of the Chiron Corporation in 2006, where he held positions as vice president and head of antibody and protein therapeutics research. Dr. Kavanaugh received his M.D. from Vanderbilt University and his B.S. in molecular biochemistry and biophysics from Yale University. He completed training in internal medicine, cardiovascular disease and molecular and cellular biology at University of California, San Francisco, and the Cardiovascular Research Institute. Dr. Kavanaugh also currently serves as an attending staff physician at the San Francisco Veterans Administration Medical Center and as an associate clinical professor of Medicine at University of California, San Francisco. since 2015.
Age | 61 |
Tenure | 9 years |
Address | 151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 |
Phone | 650 515 3185 |
Web | https://www.cytomx.com |
CytomX Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.0175) % which means that it has lost $0.0175 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (54.7503) %, meaning that it created substantial loss on money invested by shareholders. CytomX Therapeutics' management efficiency ratios could be used to measure how well CytomX Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.01 in 2024, whereas Return On Capital Employed is likely to drop (0.14) in 2024. At this time, CytomX Therapeutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 5.2 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 19.8 M in 2024.Similar Executives
Showing other executives | EXECUTIVE Age | ||
Maria Martinez | JJill Inc | 56 | |
Eva Serrano | PVH Corp | 51 | |
Mame AnnanBrown | Kontoor Brands | N/A | |
Ellen Constantinides | PVH Corp | N/A | |
Sung Ip | HK Electric Investments | 58 | |
Neala Shepherd | Duluth Holdings | 46 | |
Wai Ng | HK Electric Investments | 47 | |
Yuk Wong | HK Electric Investments | 59 | |
Marianne Schlecht | Duluth Holdings | 72 | |
Tak Yee | HK Electric Investments | 62 | |
Amber McCann | PVH Corp | N/A | |
Sanjeev Mohanty | Levi Strauss Co | N/A | |
Karla Frieders | Steven Madden | 47 | |
Ezio Garciamendez | Kontoor Brands | N/A | |
Albert Sutera | Duluth Holdings | 58 | |
Elliot Staples | JJill Inc | N/A | |
Dawn Vitale | Levi Strauss Co | N/A | |
Joseph Teklits | JJill Inc | N/A | |
Awadhesh Sinha | Steven Madden | 78 | |
Karyn Hillman | Levi Strauss Co | 56 | |
Todd Jacobs | Black Hills | 55 |
Management Performance
Return On Equity | -54.75 | ||||
Return On Asset | -0.0175 |
CytomX Therapeutics Leadership Team
Elected by the shareholders, the CytomX Therapeutics' board of directors comprises two types of representatives: CytomX Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CytomX. The board's role is to monitor CytomX Therapeutics' management team and ensure that shareholders' interests are well served. CytomX Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CytomX Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
MBA BS, Head VP | ||
Matthew Young, Independent Director | ||
Hoyoung Huh, Chairman of the Board | ||
Charles Fuchs, Director | ||
JD Rowland, General VP | ||
Danielle OlanderMoghadassian, Senior Officer | ||
YuWaye MD, Senior Officer | ||
Leslie Robbins, Senior Vice President - Intellectual Property | ||
Sean McCarthy, President CEO, Director | ||
Sean DPHIL, Chairman CEO | ||
Christopher Ogden, Principal Accounting | ||
Marcia Belvin, Senior Officer | ||
Chau MBA, Vice Communications | ||
Timothy Shannon, Independent Director | ||
John Scarlett, Director | ||
Debanjan Ray, CFO, Principal Financial and Accounting Officer | ||
Jamie Moore, VP Manufacturing | ||
Lloyd Rowland, Senior Vice President Chief Compliance Officer, General Counsel, Secretary | ||
Nick Galli, Senior Vice President Chief Business Officer | ||
Marion McCourt, Director | ||
James Meyers, Independent Director | ||
Rachel Humphrey, Chief Medical Officer | ||
Elaine Jones, Independent Director | ||
Cynthia Ladd, Senior Vice President General Counsel | ||
Michael Kavanaugh, Chief Scientific Officer and Head - Research and Non-Clinical Development | ||
Frederick Gluck, Co-Founder and Director | ||
Christopher Keenan, Vice President Investor Relations and Corporate Communications Vice President Investor Relations and Corporate Communications | ||
Robert Goeltz, CFO | ||
Neil Exter, Independent Director | ||
Hoyoung MD, Special Officer | ||
Dawn Benson, Senior Manufacturing | ||
DPHIL DPhil, Chairman CEO |
CytomX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CytomX Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -54.75 | ||||
Return On Asset | -0.0175 | ||||
Profit Margin | (0.01) % | ||||
Operating Margin | (0.02) % | ||||
Current Valuation | (17.64 M) | ||||
Shares Outstanding | 67.72 M | ||||
Shares Owned By Insiders | 1.33 % | ||||
Shares Owned By Institutions | 48.63 % | ||||
Number Of Shares Shorted | 3.53 M | ||||
Price To Earning | (11.41) X |
Pair Trading with CytomX Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CytomX Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CytomX Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with CytomX Stock
0.67 | MDGL | Madrigal Pharmaceuticals Financial Report 14th of May 2024 | PairCorr |
0.61 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
Moving against CytomX Stock
0.85 | KA | Kineta Inc Report 29th of March 2024 | PairCorr |
0.81 | TFX | Teleflex Incorporated Financial Report 2nd of May 2024 | PairCorr |
0.61 | MEIP | MEI Pharma Financial Report 9th of May 2024 | PairCorr |
0.57 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
0.52 | MCRB | Seres Therapeutics Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to CytomX Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CytomX Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CytomX Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CytomX Therapeutics to buy it.
The correlation of CytomX Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CytomX Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CytomX Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CytomX Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for CytomX Stock analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
Is CytomX Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytomX Therapeutics. If investors know CytomX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytomX Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.01) | Revenue Per Share 1.371 | Quarterly Revenue Growth 0.322 | Return On Assets (0.02) | Return On Equity (54.75) |
The market value of CytomX Therapeutics is measured differently than its book value, which is the value of CytomX that is recorded on the company's balance sheet. Investors also form their own opinion of CytomX Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytomX Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytomX Therapeutics' market value can be influenced by many factors that don't directly affect CytomX Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytomX Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytomX Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytomX Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.